CD274 and ovarian carcinoma: In the non-randomised Phase Ib/II JAVELIN PARP Medley study evaluating the PARPi talazoparib combined with the PD-L1 inhibitor avelumab, clinical activity was observed primarily in patients with BRCA-mutated tumours, with confirmed ORRs of 18% in TNBC and 64% in platinum-sensitive BRCA-mutated ovarian cancer [51].